Effects of two weeks of topical budesonide treatment on microvascular exudative responsiveness in healthy human nasal airways

European Respiratory Journal

Volumn 10, Issue 4, 1997, Pages 841-845

  Greiff, L ^a   Andersson, M ^a   Svensson, C ^a   Akerlund A ^a   Alkner, U ^b   Persson, C G A ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Astra Draco ^*  (Sweden)

Author keywords

Asthma; Glucocorticosteroids; Inflammation; Plasma exudation; Rhinitis

Indexed keywords

BUDESONIDE; GLUCOCORTICOID; HISTAMINE; PLACEBO;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EXUDATE; HUMAN; HUMAN EXPERIMENT; MICROCIRCULATION; NORMAL HUMAN; PNEUMONIA; PRIORITY JOURNAL; RHINITIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRANASAL; ADULT; ALPHA-MACROGLOBULINS; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; EXUDATES AND TRANSUDATES; GLUCOCORTICOIDS; HISTAMINE; HUMANS; NASAL LAVAGE FLUID; NASAL MUCOSA; PREGNENEDIONES; REFERENCE VALUES;

EID: 0030976597     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Persson CGA, Svensson C, Greiff L, et al. Use of the nose to study the inflammatory response in the respiratory tract (Editorial). Thorax 1992; 47: 993-1000.
2. Svensson C, Klementsson H, Alkner U, Pipkorn U, Persson CGA. Glucocorticoid-induced attenuation of mucosal exudation of fibrinogen and bradykinins in seasonal allergy rhinitis. Allergy 1994; 49: 177-183.
3. Van der Graaf EA, Out TA, Roos CM, Jansen HM. Respiratory membrane permeability and bronchial hyperreactivity in patients with stable asthma. Am Rev Respir Dis 1991; 143: 362-368.
4. Erjefält I, Persson CGA. Antiasthma drugs attenuate inflammatory leakage of plasma into airway lumen. Acta Physiol Scand 1986; 128: 653-654.
5. Miller-Larsson A, Brattsand R. Topical anti-inflammatory activity of the glucocorticoid budesonide on airway mucosa: evidence for a "hit and run" type of activity. Agents Actions 1990; 29: 127-129.
6. Boschetto P, Rogers DF, Fabbri LM, Barnes PJ. Corticosteroid inhibition of airway microvascular leakage. Am Rev Respir Dis 1991; 143: 605-609.
7. Svensjö E, Roempke K. Time-dependent inhibition of bradykinin and histamine-induced increase in microvascular permeability by local glucocorticosteroid treatment. In: Hogg JC, Ellul-Micallef R, Brattsand R, eds. Glucocorticosteroids, inflammation, and bronchial hyperreactivity. Amsterdam, Elsevier, 1985; pp. 136-144.
8. Persson CGA, Erjefält I, Alkner U, et al. Plasma exudation as a first-line mucosal defence. Clin Exp Allergy 1991; 21: 17-24.
9. Greiff L, Andersson M, Svensson C, Alkner U, Persson CGA. Glucocorticoids may not inhibit plasma exudation by direct vascular effects in human airways. Eur Respir J 1994; 7: 1120-1124.
10. Brattsand R, Selroos O. Current drugs for respiratory diseases: glucocorticosteroids. In: Page CP, Metzger WJ, eds. Drugs and the Lung. New York, Raven Press, 1994.
11. Greiff L, Andersson M, Åkerlund A, et al. Microvascular exudative hyperresponsiveness in human coronavirus-induced common cold. Thorax 1994; 49: 121-127.
12. Greiff L, Pipkorn U, Alkner U, Persson CGA. The "nasal pool device" applies controlled concentrations of solutes on human nasal airway mucosa and samples its surface exudations/secretions. Clin Exp Allergy 1990; 20: 253-259.
13. Erjefält JS, Erjefält I, Sundler F, Persson CGA. Epithelial pathways for luminal entry of bulk plasma. Clin Exp Allergy 1995; 25: 187-195.
14. Persson CGA, Erjefält I, Gustafsson B, Luts A. Subepithelial hydrostatic pressure may regulate plasma exudation across the mucosa. Int Arch Allergy Appl Immunol 1990; 92: 148-153.
15. Greiff L, Erjefält I, Wollmer P, Pipkorn U, Persson CGA. Effects of histamine, ethanol, and a detergent on exudation and absorption across the guinea-pig airway mucosa in vivo. Thorax 1991; 46: 700-705.
16. 51Cr-EDTA across the human nasal mucosa in the presence of topical histamine. Thorax 1991; 146: 630-632.
17. Erjefält I, Luts A, Persson CGA. Appearance of airway absorption and exudation tracers in guinea-pig tracheobronchial lymph nodes. J Appl Physiol 1993; 74: 817-824.
18. Gustafsson B, Persson CGA. Asymmetrical effects of increases in hydrostatic pressure on macromolecular movement across the airway mucosa. Clin Exp Allergy 1991; 21: 121-126.
19. Majno G, Palade GE. Studies on inflammation. I. The effect of histamine and serotonin on vascular permeability: an electron microscopic study. J Biophys Biochem Cytol 1961; 11: 571-605.
20. Majno G, Palade GE, Schoefl GI. Studies on inflammation. II. The site of action of histamine and serotonin along the vascular tree: a topographic study. J Biophys Biochem Cytol 1961; 11: 607-626.
21. 133Xe wash-out technique. Allergy 1983; 38: 461-464.
22. Svensson C, Pipkorn U, Alkner U, Baumgarten CR, Persson CGA. Topical vasoconstrictor (oxymetazoline) dose not affect histamine-induced mucosal exudation of plasma in human nasal airways. Clin Exp Allergy 1992; 22: 411-416.
23. Farr BM, Gwaltney Jr JM, Hendley O, et al. A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection. J Infect Dis 1990; 162: 1173-1177.
24. Erjefält JS, Erjefält I, Sundler F, Persson CGA. Effects of topical budesonide on epithelial restitution in vivo in guinea-pig trachea. Thorax 1995; 50: 785-792.
25. Erjefält I, Persson CGA. Increased sensitivity to toluene diisocyanate (TDI) in airways previously exposed to TDI. Clin Exp Allergy 1992; 22: 854-862.